Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Høiby, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; PLACEBO; QUINOLONE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

CYSTIC FIBROSIS; ERADICATION THERAPY; HUMAN; LUNG INFECTION; MEDICAL APPARATUS, EQUIPMENT AND SUPPLIES; MICROBIAL COLONIZATION; PROPHYLAXIS; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; BACTERIAL PNEUMONIA; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; REVIEW;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; HUMANS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 79953262396     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-32     Document Type: Short Survey

References (54)

1. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004, 23:146-158. 10.1183/09031936.03.00057003, 14738247.
2. Høiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001, 3:23-35.
3. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995, 310:1571-1572. 2549944, 7787647.
4. Armstrong DS, Hook SM, Jamsen KM, Nixon GM, Carzino R, Carlin JB, Robertson CF, Grimwood K. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005, 40:500-510. 10.1002/ppul.20294, 16208679.
5. Høiby N, Pressler T. Emerging pathogens in cystic fibrosis. Eur Respir Mon 2006, 35:66-78.
6. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008, 7:523-530. 10.1016/j.jcf.2008.06.009, 18693078.
7. Hoffmann N, Rasmussen TB, Jensen P, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK, Høiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 2005, 73:2504-2514. 10.1128/IAI.73.4.2504-2514.2005, 1087399, 15784597.
8. Jelsbak L, Johansen HK, Frost AL, Thøgersen R, Thomsen LE, Ciofu O, Yang L, Haagensen JA, Høiby N, Molin S. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect Immun 2007, 75:2214-2224. 10.1128/IAI.01282-06, 1865789, 17261614.
9. Bjarnsholt T, Jensen P, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Høiby N. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009, 44:547-558. 10.1002/ppul.21011, 19418571.
10. Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010, 5:1663-1674.
11. Hansen CR, Pressler T, Nielsen KG, Jensen P, Bjarnsholt T, Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 2010, 9:51-58. 10.1016/j.jcf.2009.10.005, 19939747.
12. West JB. Pulmonary Physiology and Pathophysiology 2001, Philadelphia: Lippincott Williams & Wilkins.
13. Høiby N. P. aeruginosa in cystic fibrosis patients resists host defenses, antibiotics. Microbe 2006, 1:571-577.
14. Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van Gennip M, Ciofu O, Mandsberg L, Kharazmi A, Döring G, Givskov M, Høiby N, Jensen P. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 2010, 65:57-62. 10.1136/thx.2009.114512, 19846469.
15. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984, 105:117-124. 10.1016/S0022-3476(84)80375-3, 6376743.
16. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340:23-30. 10.1056/NEJM199901073400104, 9878641.
17. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B, . Cystic Fibrosis Therapeutics Development Network Study Group Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167:841-849. 10.1164/rccm.200208-855OC, 12480612, Cystic Fibrosis Therapeutics Development Network Study Group.
18. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122:219-226. 10.1378/chest.122.1.219, 12114362.
19. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006, 57:306-311. 10.1093/jac/dki461, 16396919.
20. Permin H, Koch C, Høiby N, Christensen HO, Møller AF, Møller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother 1983, 12(Suppl A):313-323.
21. Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makholm LM, Rock MJ, Splaingard ML. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003, 36:230-240. 10.1002/ppul.10336, 12910585.
22. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 2002, 34:232-236. 10.1002/ppul.10135, 12203855.
23. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008, 68:223-240. 10.1111/j.1365-2958.2008.06152.x, 18312276.
24. Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987, 19:831-838. 10.1093/jac/19.6.831, 3301785.
25. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338:725-726. 10.1016/0140-6736(91)91446-2, 1679870.
26. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000, 16:749-767.
27. Döring G, Høiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91.
28. Heijerman H, Westerman E, Conway S, Touw D, Döring G, . Consensus Working Group Inhaled medication and inhalation devices for lung diseases in patients with cystic fibrosis: a European consensus. J Cystic Fibros 2009, 8:295-315. Consensus Working Group.
29. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009, 54:658-669. 10.4187/aarc0537, 19393109.
30. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007, 42:307-313. 10.1002/ppul.20594, 17352404.
31. Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, Heijerman HG. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros 2007, 6:284-292. 10.1016/j.jcf.2006.10.010, 17185047.
32. Duff AJ, Latchford GJ. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it. J Cyst Fibros 2010, 9:455-456. 10.1016/j.jcf.2010.08.012, 20840889.
33. Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, Henry MM, Leigh MW. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol 2010, 45:281-290.
34. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009, 135:1223-1232. 10.1378/chest.08-1421, 2818415, 19420195.
35. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928. 10.1164/rccm.200712-1804OC, 2577727, 18658109.
36. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010, 45:1121-1134. 10.1002/ppul.21301, 20672296.
37. Baumann U, Stocklossa C, Greiner W, von der Schulenburg JM, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003, 2:84-90. 10.1016/S1569-1993(03)00024-9, 15463855.
38. Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005, 4:49-54.
39. Tramper-Stranders GA, Wolfs TF, van Haren Noman S, van Aalderen WM, Nagelkerke AF, Nuijsink M, Kimpen JL, van der Ent CK. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 2010, 65:915-920. 10.1136/thx.2009.126128, 20729233.
40. Yousef AA, Jaffe A. The role of azithromycin in patients with cystic fibrosis. Paediatr Respir Rev 2010, 11:108-114. 10.1016/j.prrv.2009.12.003, 20416547.
41. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, . AZ0004 Azithromycin Study Group Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010, 303:1707-1715. 10.1001/jama.2010.563, 20442386, AZ0004 Azithromycin Study Group.
42. Treggiari M, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, . EPIC Study Group Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009, 30:256-268. 10.1016/j.cct.2009.01.003, 2783320, 19470318, EPIC Study Group.
43. Treggiari M, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kronmal R, Ramsey B, Accurso F, . EPIC Investigators Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis [Abstract]. J Cyst Fibros 2010, 9:54. EPIC Investigators.
44. Høiby N, Hansen CR, . group Scandinavian Cystic Fibosis Study Group: Prevention of chronic P. aeruginosa infection by antibiotic treatment of intermittent colonization in patients with cystic fibrosis: nebulized colistin + oral ciprofloxacin and azithromycin compared with colistin + oral ciprofloxacin. 2009, Copenhagen: Danish Cystic Fibrosis Center, Rigshospitalet Denmark, group.
45. Trapnell BC, Rolfe M, McColley S, Montgomery AB, Moorehead L, Geller D. Fosfomycin/tobramycin for inhalation (FTI): efficacy results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa [Abstract]. Pediatr Pulmonol 2010, 45:302.
46. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010, 35:322-332.
47. Wang H, Wu H, Song Z, Høiby N. Ciprofloxacin shows concentration-dependent killing of P. aeruginosa biofilm in vitro [Abstract]. J Cyst Fibros 2010, 9:41.
48. Wang H, Wu H, Song Z, Høiby N. Colistin shows concentration-dependent killing of Pseudomonas aeruginosa biofilm in vitro [Abstract]. Pediatr Pulmonol 2010, 45(suppl. 33):314.
49. Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G. Colistin-tobramycin combinations are superior to monotherapy concerning killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010, 202:1585-1592. 10.1086/656788, 20942647.
50. Haagensen J, Klausen M, Ernst RK, Miller SI, Folkesson A, Tolker-Nielsen T, Molin S. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 2007, 189:28-37. 10.1128/JB.00720-06, 1797205, 17041046.
51. Frederiksen B, Pressler T, Hansen A, Koch C, Høiby N. Effect of aerosolised rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 2006, 95:1070-1074. 10.1080/08035250600752466, 16938752.
52. Smyth AR, Cifelli PM, Ortori CA, Righetti K, Lewis S, Erskine P, Holland ED, Givskov M, Williams P, Cámara M, Barrett DA, Knox A. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis: a pilot randomized controlled trial. Pediatr Pulmonol 2010, 45:356-362.
53. Tolker-Nielsen T, Høiby N. Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy. Future Microbiol 2009, 4:645-647. 10.2217/fmb.09.38, 19659420.
54. Döring G, Elborn JS, Johannesson M, de Jonge H, Griese M, Smyth A, Heijerman H, . Consensus Study Group Clinical trials in cystic fibrosis. J Cyst Fibros 2007, 6:85-99. Consensus Study Group.